Jefferies analyst Suneet Kamath maintains $MetLife (MET.US)$ with a buy rating, and adjusts the target price from $81 to $95.
According to TipRanks data, the analyst has a success rate of 71.0% and a total average return of 9.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $MetLife (MET.US)$'s main analysts recently are as follows:
MetLife is anticipated to unveil its upcoming five-year strategic plan, dubbed 'New Frontier', on December 12. Observations based on recent commentary and financial outcomes indicate that the company may establish a new benchmark for a sustainable 16-18% return on equity (ROE), considered quite remarkable in the US Life sector since the Global Financial Crisis (GFC). This level of sustainable ROE, along with the decreasing concerns related to variable investment income (VII) and commercial real estate (CRE), is expected to garner investor interest and contribute to potential appreciation in the company's share value.
Many investors have perceived MetLife as a non-dynamic stock for a considerable portion of the year, with concerns stemming from spread compression in Retirement Income Solutions, persistently subpar alternative investment returns, a disproportionately large commercial mortgage loan portfolio in the office sector, and intensifying rivalry in its fundamental group benefits segment. However, upon reviewing these factors over the next 6-12 months and comparing MetLife with major peers in the industry, there appears to be a compelling argument for MetLife's potential relative valuation improvement.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
富瑞集團分析師Suneet Kamath維持$大都會人壽 (MET.US)$買入評級，並將目標價從81美元上調至95美元。
根據TipRanks數據顯示，該分析師近一年總勝率為71.0%，總平均回報率為9.5%。
此外，綜合報道，$大都會人壽 (MET.US)$近期主要分析師觀點如下：
預計大都會人壽將於12月12日公佈其即將推出的名爲 「新前沿」 的五年戰略計劃。基於近期評論和財務業績的觀察表明，該公司可能會爲可持續的16-18％的股本回報率（ROE）建立新的基準，自全球金融危機（GFC）以來，這在美國人壽領域被認爲相當可觀。這種可持續的投資回報率，加上與可變投資收益（VII）和商業地產（CRE）相關的擔憂減少，預計將引起投資者的興趣，並促進公司股票價值的潛在升值。
許多投資者在一年中的大部分時間裏都將大都會人壽視爲非動態股票，其擔憂源於退休收入解決方案的利差壓縮、另類投資回報持續低於標準水平、辦公行業的商業抵押貸款組合不成比例地龐大，以及其基本群體福利板塊的競爭加劇。但是，在審查未來6-12個月的這些因素並將大都會人壽與業內主要同行進行比較後，似乎有令人信服的論據表明大都會人壽的相對估值可能有所提高。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
